Parental and parent-perceived child interest in clinical trials for food allergen immunotherapy

Food allergy (FA) affects an estimated 8% of children in the United States and is associated with negative psychosocial effects on children with FA and their caregivers, as well as substantial economic burden.1–3 No approved treatment for FA exists, but several experimental therapies are presently under investigation, including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT).4 These therapies aim to desensitize patients through administration of gradually increasing doses of allergen, with goals ranging from protection against accidental ingestion to the development of sustained unresponsiveness with ad libitum allergen exposure.

http://ift.tt/2I8VV86